Sarah Sewaralthahab

Dr. Sarah Sewaralthahab

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in American Journal of Hematology
Verified
Journal Article
Open access
HAHanny Al-Samkari
Hanny Al-Samkari
RKRaj S. Kasthuri
Raj S. Kasthuri
HMHans‐Jurgen Mager
Hans‐Jurgen Mager
JZJenny Y. Zhou
Jenny Y. Zhou
MSMarcelo M. Serra
Marcelo M. Serra
MFMarie E. Faughnan
Marie E. Faughnan
Hereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT‐specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician‐investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. Search Strategy and Selection Criteria: Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4–13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to be retrieved for further review. All retrieved full texts were then reviewed to reach a final determination if a study met the inclusion criteria. Included references were then compiled into evidence tables, which were then utilized by the International Consensus Report Working Group throughout the development of report recommendations.

2 January 2018 in Hemoglobin
Verified
Journal Article
Closed access
SSSarah Sewaralthahab
Sarah Sewaralthahab
JMJay Menaker
Jay Menaker
JLJennie Y. Law
Jennie Y. Law
A 25-year-old female with sickle cell anemia presented with respiratory failure due to acute chest syndrome (ACS). Given her severely compromised cardiopulmonary status, she was started on veno-venous extracorporeal membrane oxygenation (VV-ECMO). After 20 days, the patient’s respiratory status improved and she was successfully decannulated. Veno-venous extracorporeal membrane oxygenation can be utilized for severe ACS in adult patients with sickle cell disease. Prompt initiation of this modality may improve outcomes in adult patients with sickle cell disease complicated by life threatening ACS.

25 November 2022 in World Neurosurgery
Verified
Journal Article
Closed access
SBSarah Basindwah
Sarah Basindwah
MAMusaad AlHamzah
Musaad AlHamzah
FBFatima Balsharaf
Fatima Balsharaf
BABalqes AlRajhi
Balqes AlRajhi
SSSarah Sewaralthahab
Sarah Sewaralthahab
AAAmro Al-Habib
Amro Al-Habib

28 November 2024 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
SSSarah Sewaralthahab
Sarah Sewaralthahab
ZSZara Sayar
Zara Sayar
SKShrey Kohli
Shrey Kohli
RZRebecca L. Zon
Rebecca L. Zon
AIAaron F.J. Iding
Aaron F.J. Iding
LPLauren G. Poole
Lauren G. Poole

30 November 2020 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
SFSaira Farid
Saira Farid
SSSarah Sewaralthahab
Sarah Sewaralthahab
HSHedy Patricia Smith
Hedy Patricia Smith
A 57-year-old man with mild haemophilia B was admitted for coronary artery bypass graft surgery. His factor IX (FIX) activity was 15% on admission. Our goal was to maintain his FIX activity at 80%–100% for post-op days (PODs) 0–3, and at 60%–80% for PODs 4–14. Preoperatively, the patient was given recombinant FIX (rFIX) bolus using the formula: Dosage needed=%(desired FIX level−current level of FIX)×weight (kg)×1.3. This increased his activity to 100%. One IU of rFIX increased FIX activity by 0.8%; the half-life of rFIX is 18–24 hours. The rFIX infusion was started intraoperatively and continued after surgery to maintain target FIX activity. He was discharged on POD 9 on rFIX bolus dosing of 5000 IU every 12 hours for an additional 5 days. Using continuous factor infusion, we managed to decrease the amount rFIX used by >60% while maintaining steady state FIX activity level.

1 December 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
ISIlana Schlam
Ilana Schlam
Kelly A. HirkoKelly A. Hirko
Kelly A. Hirko
DSDaniela Shveid
Daniela Shveid
IAInas Abuali
Inas Abuali
SSSarah Sewaralthahab
Sarah Sewaralthahab
Dario TrapaniDario Trapani
Dario Trapani
PURPOSE: Trimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM), and postmastectomy radiation therapy. Although broadly considered the best approach for IBC, in the United States, only a third of patients receive TMT. The rate is unknown in low- and middle-income countries (LMICs). METHODS: A questionnaire in English and Spanish was constructed to assess the awareness, knowledge, and treatment patterns of IBC among providers in LMICs. It was emailed to the ONCOLLEGE global oncology collaborative group (a network of cancer care providers practicing in LMICs) and through other oncology network providers in LMICs, enhancing the sample size through a snowball sampling approach. RESULTS: Between June and December of 2023, 145 participants completed the questionnaire, of whom 112 respondents were from 36 LMICs. All the providers reported that standard chemotherapy and MRM were available in their practice; 99.5% responded that radiation therapy was available. A total of 74.1% appropriately reported that IBC is a clinical diagnosis, although 51.8% stated that pathologic evidence of lymphatic emboli was required for IBC diagnosis. A third of the providers responded that >90% of their patients undergo all three parts of TMT. CONCLUSION: Many patients with IBC in LMICs are not receiving TMT. Barriers to diagnosis and treatment were at least partially related to limited providers' comfort level and knowledge, suggesting that educational approaches can be impact-oriented interventions. On the basis of our findings, we created educational material, which will be translated into various languages and disseminated broadly to improve providers' awareness and knowledge of IBC.